摘要
[目的]分析评价肺癌化疗患者临床路径实施效果。[方法]采用同期对照法,选取2013年1月1日至2013年12月31日在辽宁省肿瘤医院住院的254例肺癌化疗患者为研究对象,其中符合肺癌化疗临床路径纳入标准的201例患者为临床路径组,其他53例患者为非临床路径组。对比分析两组患者的平均住院日、费用构成比,分析肺癌化疗患者的入径率、入径完成率。[结果]临床路径组平均住院日小于非临床路径组,约有56%的患者平均住院日达到标准住院日要求,临床路径组平均住院费用小于非临床路径组。肺癌化疗患者临床路径入径率79.13%,入径完成率89.1%。[结论]肺癌化疗患者临床路径管理可以有效缩短住院日、在一定程度上控制了住院费用的增长。
[Purpose] To investigate and evaluate the effect of clinical pathway in patients with lung cancer chemotherapy. [Methods] The 254 patients with lung cancer chemotherapy from January,2013 to December,2013 in Liaoning Cancer Hospital were enrolled, among which 201 patients met the 2009 regulations lung cancer clinical pathway were divided into clinical pathway group,and the other 53 patients as non-clinical pathway group. The average hospitalization days,cost constitute were analyzed in two groups,and clinical pathway completion rate in the patients with lung cancer was evaluated. [Results] The average hospitalization days in clinical pathway group was less than that in non-clinical pathway group;about 56% of the average hospitalization days was up to standard hospitalization requirements. The average hospitalization cost in clinical pathway group was less than that in non-clinical pathway group. Chemotherapy in patients with lung cancer clinical pathway into diameter ratio was 79.13%,the clinical pathway completion rate was 89.1% in patients with lung cancer chemotherapy. [Conclusion] The clinical pathway management of lung cancer patients with chemotherapy can effectively shorten the hospitalization days and control the hospitalization cost to a certain extent.
出处
《中国肿瘤》
CAS
2016年第3期187-189,共3页
China Cancer
关键词
肺癌
化疗患者
临床路径
评价
控制策略
lung cancer
chemotherapy patients
clinical pathway
evaluation
control strategy
